title: Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life.
abstract: BACKGROUND
  The hypothesis was that torasemide, due to more predictable pharmacokinetics/pharmacodynamics, induces greater improvements in functional and social limitation than furosemide and reduces the frequency of hospitalisations in primary care patients with chronic heart failure (CHF).
  
  
  METHODS
  Prospective, randomized, unblinded study in primary care, 237 patients with CHF (NYHA II-IV), all on ACE inhibitors. Randomisation: torasemide (n=122) or furosemide (n=115), treated for 9 months.
  
  
  METHODS
  Clinical efficacy, quality of life, safety, tolerability, hospitalisations.
  
  
  RESULTS
  Clinical improvement was observed in both groups, but the trend to improve by at least one NYHA class was significant only in torasemide- (P=0.014), but not in furosemide-treated patients. There were no differences with regard to adverse events and hospitalisation due to CHF. Overall, tolerability (P=0.0001) and improvement in daily restrictions (P=0.0002) were significantly higher, number of mictions at 3, 6 and 12 h after diuretic intake (P<0.001 at all time points) and urgency to urinate (P<0.0001) significantly lower in torasemide- vs. furosemide-treated patients.
  
  
  CONCLUSIONS
  CHF patients treated with torasemide gain a higher benefit in quality of life than furosemide treated patients, due to torasemide's dual effect on both clinical status and social function.
authors.affiliation: Roche Pharmaceuticals Switzerland, CH-4153 Reinach, Switzerland.
authors.forename: Karin
authors.initials: K
authors.lastname: Müller
authors.forename: Giancesare
authors.initials: G
authors.lastname: Gamba
authors.forename: Françoise
authors.initials: F
authors.lastname: Jaquet
authors.forename: Bernhard
authors.initials: B
authors.lastname: Hess
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D002908:Chronic Disease; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005665:Furosemide / Q000009:adverse effects / Q000627:therapeutic use*; D006333:Heart Failure / Q000145:classification / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011320:Primary Health Care; D011446:Prospective Studies; D011788:Quality of Life; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D000077786:Torsemide; D016896:Treatment Outcome
chemical_list: D004232:Diuretics; D013449:Sulfonamides; D005665:Furosemide; D000077786:Torsemide